anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Discharge from hospital has been highlighted as a critical time in the care of individuals with mental illness. The peak period of risk for readmission for individuals with severe mental illness is in the first month and the highest risk for post-discharge suicide is within the first 2 weeks with discontinuity of contact with providers highlighted as a key risk factor. One half of individuals with schizophrenia miss their first-scheduled outpatient appointment following discharge and this time is a key period of risk for medication non-compliance. Common problems that occur at the time of discharge from psychiatric care settings include poor communication between inpatient and outpatient providers and inadequate involvement and support of families. The research literature on effective practices linked with discharge is strikingly sparse given the evidence that this is a period of heightened risk.

The investigators hypothesize that the Welcome Basket intervention will improve the discharge-related outcomes of individuals with schizophrenia or bipolar disorder with psychotic features compared to treatment as usual. Investigators will also explore the outcomes of an abbreviated, 2-visit version of the intervention. This study will employ a randomized, controlled trial design. Inpatient clients with a diagnosis of schizophrenia spectrum mental illness or bipolar disorder with psychotic features will be randomized with a 2:2:1 ratio to: treatment as usual, the full welcome basket intervention, and the abbreviated intervention. Measures will include re-hospitalization, symptomatology, quality of life, and community functioning. Assessments at baseline, 4 weeks post-discharge, and 6 months post-discharge will facilitate studies of relative effectiveness and sustainment of gains. This design will facilitate an examination of both overall outcomes as well as some preliminary dismantling of mechanisms of action.
The present invention provides methods of treating a coronavirus, COVID-19 disease. COVID-19 disease is caused by the coronavirus, SARS-COV-2.Treatment of the SARS-COV-2 infection could be achieved by administering a single element or a combination of elements in the protocol of therapies comprising of1) A laxative2) A Nutritious Meal followed by a cup of green tea, raw honey, lemon. milk and a dessert of pear d'anjou and strawberries3) Administering drugs and vitamins. These drugs could be anti-parasitic, antiviral, antibacterial and/or immunomodulatory.4) Providing for the subject infected with the SARS-COV-2 to enjoy the treat of a plain water hot bathtub bath. Some Epsom Salt should be added to the plain water hot bathtub bath. The subject should be encouraged to spend at least 30 minutes in the hot bathtub bath.5) A Physical Exercise session.6 Claims, 0 Drawing Sheets.
Effective rehabilitation after acquired brain injury is essential for reducing the impact of the leading cause of pediatric disability in the United States. Neuroplastic changes in response to physical therapy are likely different in children compared to adults because children are continuing to experience developmental brain maturation while also experiencing the neural changes associated with injury and rehabilitation. The interaction between these two processes is poorly understood but presumably critical for maximizing long term outcomes. Using biomarkers to measure and predict rehabilitation-induced changes will improve rehabilitation prognosis and will facilitate the development of rehabilitation interventions that optimize neuroplastic potential in children. The objectives of this pilot study are to investigate the motor and neural responses to two different rehabilitation programs in children and adolescents with chronic hemiplegia from prior stroke. Participants will be randomly assigned to receive conventional physical therapy or an asymmetrical gait training program. Conventional physical therapy will include activities such as gait and balance training and muscle strengthening. The asymmetrical gait training program uses new technology to train each leg at a different speed during walking practice. Measurements of motor and neural function will occur at five timepoints before, during and after treatment. Motor function measures will include gait symmetry ratios, walking speed, community step activity, and participant and caregiver ratings on self-identified walking goals. Neural measures will include motor response characteristics of muscle contractions elicited in two lower extremity muscles by transcranial magnetic stimulation of the injured cortex. We will also establish a genetic database to identify the presence or absence of two genetic variants \[Apolipoprotein E (ApoE Є4) and val66met Brain-derived neurotropic factor (BDNF) polymorphisms\] associated with decreased potential for neuroplasticity for planning future investigations. The results will be used to inform the design of larger studies evaluating physical therapy treatments that maximize the capacity of the child's brain to change after neurological injury and identifying predictors of rehabilitation-induced neuroplasticity in children.
PURPOSE:To provide a therapeutic agent for animal mastitis, reduced in the amount of used antibiotics and safely exhibiting a satisfactory effect in a short time. CONSTITUTION:This therapeutic agent for animal mastitis contains a Cupressaceae plant. As the Cupressaceae plant, any part of leaves, branches and timbers may be used and the timber part is especially priferable. In addition, this Cupressaceae plant is used in the form of a substance extracted with various kinds of organic solvents, a mixture of an organic solvent and water or water, its essential oil obtained by steam distillation or dry distillation or the active component in the extract or the essential oil, e.g. hinokitiol, beta-dolablin or carvacrol. As the Cupressaceae plant, Thujopsisdolabrata var. hondai, Thujopsis dolabrata sieb. et Zucc., belonging to Thujopsis, Juniperus chinensis L., Juniperus conferta Part. belonging to Juniperus, Thuja standishii Carr., Thuja plicata belonging to Thuja, Libocednus decurrens belonging to Libocednus or Chamaecyparis obtusa belonging to Cupressaceae family, especially Thujopsisdolabrata var. hondai is preferably used.
Sciatica is a condition of radicular pain in the leg and is usually caused by herniation of a lumbar intervertebral disc. The herniated disc compresses a lumbar nerve root that continues its route into the sciatic nerve. About 13% to 40% of all people will suffer from sciatica at least once during their lifetime. Sciatica can have severe socio-economic effects; patients are immobilised by the pain they experience and therefore cannot go to work or participate in social events. Most cases resolve spontaneously with conservative therapy using only standard analgesics and/or physiotherapy. In a large RCT it was demonstrated that outcome of conservative and surgical therapy was comparable after 26 weeks. With this knowledge the guidelines for surgical treatment of sciatica were adjusted and it is nowadays usual care to offer surgery only after at least 8 weeks of conservative care and preferably after 14-16 weeks of conservative care. This decision is made together with the patient in a process of Shared Decision making. Although this treatment regimen has been demonstrated to be efficacious and cost effective, the burden for a patient during these weeks of conservative care is usually high. The investigators seek to find a type of conservative care to reduce the discomfort due to the pain and to enable the patient to remain physically active. Not only will this add to the quality of life of the patient, but it will also prevent the patient from taking a sick-leave. In this study, patients will be randomized to either treatment with transforaminal epidural injections or to standard care consisting of oral pain medication.
BACKGROUND: Vesicourethral anastomosis stenosis (VUAS) refers to the diameter narrowing of a vesicourethral anastomosis (VUA). It is a known complication after radical prostatectomy that nowadays presents in less than 1% of these cases. When the lumen narrows sufficiently to impede urine flow, obstructive symptoms arise. While the incidence of VUAS used to be notably higher prior to the widespread use of the robotic approach, traditional procedures still fail in up to 42% of cases. Initial management typically involves endoscopic procedures, such as dilation, incision, or resection. If these approaches prove ineffective, VUA reconstruction is warranted. Following the resection of the unhealthy urethra, a potential drawback is the insufficient length of the healthy proximal urethral to reach the bladder without tension. In such cases, urinary diversion with an ileal conduit is an option. However, when the patient prefers to maintain an orthotopic urinary tract configuration, there is limited guidance in the literature regarding surgical techniques.
OBJECTIVE: To outline the indications, describe the step-by-step technique, and evaluate the outcomes of transperineal urethral advancement to facilitate a tension-free VUA.
MATERIALS: We first discuss the indications to identify which patients are candidates for this procedure. Then, a step-by-step description of the robotic VUA revision assisted by transperineal urethral mobilization is presented. Detailed steps and helpful hints are included. Finally, we outline the postoperative pathway and expected outcomes.
RESULTS: This technique allows patients with VUAS to preserve the orthotopic configuration of the urinary tract when a tension-free anastomosis proves challenging. Although urinary incontinence is expected, an artificial urinary sphincter could be placed in the following months.
CONCLUSION: The robotic management of complex vesicourethral anastomosis stenosis with transperineal urethral advancement is a feasible and safe procedure that requires the interdisciplinary management of robotic and reconstructive urologists.
The invention discloses an oil-control acne-removing moisturizing plant mite-removing deep-layer skin-cleaning facial cleanser and a preparation process thereof. The facial cleanser contains plant extract composition such as herba Rosmarini officinalis, herba Taraxaci, radix Isatidis, caulis Et folium Brassicae Capitatae blue, Glycyrrhrizae radix, and rhizoma Helminthostachydis Zeylanicae, which can emit a special fragrance with strong mite removing effect. The Lipacide C8G (caprylyl glycine) contained in the skin care product can penetrate into pores and hair to clean dirt, and is cooperated with the shale oil sodium sulfate and the plant extract to effectively regulate the water-oil balance of skin, so that the obvious oil control effect is presented. The plant extract composition has strong nutrition and moisture-keeping effects, injects pure and natural moisture-keeping power into the skin, and is cooperated with blue massage particles to wake up water and activate the skin environment, assist in nutrition absorption, relieve the dryness and itching of the skin and enable the skin to be full and to present elastic, healthy and glossy. The white willow bark extract, the honeysuckle extract, the forsythia extract, the white mulberry bark extract and the like have strong antibacterial, acne removing, whitening and anti-aging effects. The product keeps subacidity, is mild and has no stimulation.
<P>PROBLEM TO BE SOLVED: To provide a polymer useful as a drug delivery system with improved biocompatibility.  <P>SOLUTION: The polymer may be made from a zwitterionic monomer having controlled structure and molecular weight, using living polymerization such as group or atom transfer radical polymerization. For instance, the polymer may be formed by atom transfer radical polymerization using a copper chloride catalyst, a ligand which is water soluble, and a water-soluble tertiary alkyl halide initiator to form a homopolymer having a controlled polydispersity of less than 1.5 and a block copolymer with other hydrophilic or hydrophobic monomers. One suitable zwitterionic monomer is 2-methacryloyloxy-2'-trimethylammoniumethyl phosphate inner salt. The block copolymer may spontaneously form micelles, and have zwitterionic, for instance phosphorylcholine, groups at the external surface.  <P>COPYRIGHT: (C)2009,JPO&INPIT
PURPOSE:To make it possible to manufacture with extreme simplicity a bioactive apatite membrane which is similar to a bone in an organism without performing heat treatment by a method wherein a base material and a glass wherein CaO and SiO2 are at least main ingredients are faced each other in a definite distance or less; the glass ingredient is eluted and a membrane of hydroxyapatite which is similar to the bone is formed on the surface of the main material by immersing in an aq. soln. which is unsatd. to hydroxyapatite. CONSTITUTION:At least main ingredients consist of CaO and SiO2. It is pref. that CaO is 20-70mol%; SiO2 is 30-80mol%; the total of CaO and SiO2 is 65mol% or more. When such a glass that does not contain P2O5 and contains CaO and SiO2 as the main ingredients is used, it is necessary that the water solution contains phosphorus ion which is a main constituting ingredient of apatite. In addition, when such a glass that contains P2O5 and CaO and SiO2 as the main ingredients is used, it is not necessary that the water solution contains phosphorus ion which is a main constituting ingradient of apatite. In addition, when such a glass that contains CaO and, SiO2 as the main ingredients and additionally contains P2O5 is used as a glass, the water solution is selected within a range of 0-0.1mM Ca<2+> and 0-5,000mM HPO4<2->.
Gemcitabine + albumin-paclitaxel +PD-1, these drugs are given on d1, d8, 21 days as one cycle, 6-8 cycles. SBRT is performed during the third cycle.
1,147,348. Suspensions of acetyl salicylic acid. M. FAEGES. 2 Dec., 1966, No.53979/66. Heading A5B. A stable suspension of powdered solid acetyl salicylic acid mechanically dispersed in glycerin or propylene glycol may be prepared by the slow mechanical mixing of the solid acetylsalicylic acid, preferably of appropriately 100 micron particle size, so that no pressure decomposition of the acetylsalicylic acid takes place, with the glycerin or propylene glycol, in a weight-volume proportion of from 8 to 10 grams of acetyl salicylic acid to yield 30 cc. of product. The glycerin or propylene glycol is preferably anhydrous. The suspension, which can be used internally or externally, may also contain sweetening agents, e.g. sodium saccharine or sodium cyclamate, and/or flavouring substances.
In the experimental arm, patients and their treating physician will be made aware of the molecular relapse (positive ctDNA detection results) in study steps 1 (ctDNA monitoring). To locate metastatic deposits, patients will be offered to undergo a whole-body imaging with 18F-FDG PET-CT and 68Ga-FAPI-46-PET-CT, in addition to any other workup considered as relevant by their treating physician.
The present invention relates to screening methods for diagnosis, prognosis, or susceptibility to cancer in a subject by means of detecting the presence of serum autoantibodies to specific annexin protein antigens in sera from subjects. The present invention also provides screening methods for diagnosis and prognosis of cancer in a subject by means of detecting increased expression levels of annexin proteins in biological samples of the subject.  The method of the invention can also be used to identify subjects at risk for developing cancer. The method of the invention involves the use of subject derived biological samples to determine the occurrence and level of expression of annexin proteins or expression of annexin derived peptides or antigens, and/or the occurrence and level of circulating autoantibodies to specific annexin protein antigens. The present invention further provides for kits for carrying out the above described screening methods. Such kits can be used to screen subjects for increased levels of annexin proteins, or for the detection of autoantibodies to annexin proteins, as a diagnostic, predictive or prognostic indicator of cancer.
OBJECTIVE: To observe the effect of heat-sensitive moxibustion combined with medication on orthostatic hypotension (OH) of yang -qi deficiency in the elderly.
METHODS: Sixty elderly patients with OH of yang -qi deficiency were randomly divided into an observation group (30 cases, 1 case dropped out) and a control group (30 cases). The patients in the control group were treated with oral midodrine hydrochloride tablets, 2.5 mg each time and twice daily, while the patients in the observation group were treated with heat-sensitive moxibustion in addition to the treatment in the control group. Acupoints selected included Dazhui (GV 14), Fengfu (GV 16), and Baihui (GV 20), with each session lasting 30-40 min, once daily. Both groups were treated for 4 weeks. Blood pressure in the supine and standing positions, as well as the decrease of blood pressure when the position changing from supine to standing, were measured before treatment and after 2 and 4 weeks of treatment. Clinical efficacy was also evaluated.
RESULTS: After 4 weeks of treatment, both groups showed an increase in systolic blood pressure (SBP) and diastolic blood pressure (DBP) in both the supine and standing positions (P<0.05), and the decrease in SBP and DBP when the position changing from supine to standing was reduced (P<0.05). Compared with the control group, the observation group had higher SBP and DBP in both positions and a smaller decrease in SBP and DBP when the position changing from supine to standing (P<0.05). The total effective rate was 96.6% (28/29) in the observation group, which was higher than 70.0% (21/30) in the control group (P<0.05).
CONCLUSION: Heat-sensitive moxibustion combined with medication could increase the blood pressure in both supine and standing position, and decrease the reducing of blood pressure when the position changing from supine to standing in elderly patients with OH of yang-qi deficiency.
The EUC condition (Brief NOURISH-T+) engages parents in one information session moderated by a USF-based interventionist using videoconferencing. Session content is taken from the publicly available We Can! Manual. Parents in this group will receive nationally available web-based brochures on pediatric overweight/obesity on two occasions during the 6 weeks that NOURISH-T+ families participate in the study. Check-ins will take place at 2-, 4-, 8-, and 10- months post-intervention.
FIELD: biotechnology, genetic engineering, recombinant microorganisms. SUBSTANCE: method involves insertion of the foreign chromosomal or plasmid DNA in the parent microorganism by methods of genetic engineering followed by selection by sowing recombinant microorganism on nutrient media. The parent microorganism is the strain Francisella tularensis subspecies holarctica R, VKPM B-6854. Method ensures to obtain virulence factors of protein and polysaccharide nature. By this method the following recombinant strains were obtained: Francisella tularensis subsp. holarctica R55 VKPM B-6853 - a producer of virulence factor Fr. tularensis nearctica Shu, Fr. tularensis subsp. holarctica RN4, VKPM B-6855 - producer of virulence factor Ps. pseudomallei C-141, Fr. tularensis subsp. holarctica R1A VKPM B-6852 - a producer of virulence factor Fr. tularensis nearctica B-399 A Cole. Strains can be used for production of highly specific diagnostic, sera, chemical vaccines, immunomodulators and other preparations. EFFECT: improved method of preparing.
Acetaminophen (APAP) poisoning is the most frequent cause of acute hepatic failure in the United States. Toxicity requires cytochrome P-450 bioactivation of APAP. Children are less susceptible to APAP toxicity; the current theory is that they have different metabolism than adults. However, children's liquid preparations of APAP contain excipients which have been shown to inhibit APAP bioactivation in vitro and in rodents. Children tend to ingest liquid preparations, which could potentially explain their decreased susceptibility instead of an intrinsically different metabolism. Further, our review of Poison Center epidemiologic data shows that liquid preparations are less toxic in adults. Our hypothesis is that excipients in liquid preparations inhibit the bioactivation of APAP. The design is a pharmacokinetic cross-over study in humans. Healthy adult subjects will be recruited for administration of therapeutic doses of APAP in capsule and liquid formulations. Plasma via a heplock will be collected at serial time points up to 8 hours and assayed for APAP and its metabolites. After a washout period, subjects will receive the same dose of APAP in the alternate preparation. The pattern of metabolites, indicating the activity of the bioactivating enzymes, will be compared. A significant difference in P-450 metabolites will support the hypothesis and provide preliminary data for studies in patients who have ingested potentially toxic doses of APAP. Ultimately, this work could support development of novel antidotal therapy for APAP overdose.
Modern therapies and treatment algorithms, such as the treat‑to‑target strategy, have significantly improved outcomes in patients with rheumatoid arthritis (RA) over the past decades. Moreover, the concept of the "window of opportunity" has led to earlier diagnosis and better treatment outcomes. Nevertheless, progressive disease remains a significant clinical issue and socioeconomic burden, which warrants investigation of novel strategies. One of such innovative therapies is primary prevention: treating patients at risk for developing RA for a short period of time to prevent the disease before it occurs. The initiation of treatment in preclinical phases of RA is expected to delay, halt, or even prevent the disease onset or progression in the long term. This review summarizes this new concept, discusses current studies including an overview of therapeutic algorithms and findings, and provides a critical evaluation of pharmacologic approach in the preclinical stages of RA.
BACKGROUND: The prevention of methicillin-resistant S. aureus (MRSA) transmission in the healthcare setting is a priority in Infection Control practices. A cornerstone of this policy is contact tracing of nosocomial contacts after an unexpected MRSA finding. The objective of this retrospective study was to quantify the rates of MRSA transmission in different clinical settings.
METHODS: This multi-centre study included MRSA contact screening results from two regional hospitals and one academic hospital. MRSA contact tracing investigations from 2000 until 2019 were reviewed and post-contact screening results were included of index patients with an MRSA-positive culture and their unprotected contacts. Available typing results were used to rule out incidental findings.
RESULTS: Of 27,377 contacts screened after MRSA exposure, 21,488 were Health Care Workers (HCW) and 4816 patients. Post-contact screening was initiated for a total of 774 index cases, the average number of screened contacts per index case was 35.7 (range 1 to 640). MRSA transmission was observed in 0.15% (41) of the contacts, 19 (0.09%) HCW and 22 (0.46%) patients. The number needed to screen to detect one MRSA transmission was 667. The highest risk of MRSA transmission occurred during patient-to-patient contacts, with transmission rates varying from 0.32 to 1.32% among the participating hospitals. No transmissions were detected in HCW (n=2834) in the outpatient setting, and the rate of transmissions among HCW contacts on the wards was 0.13% (19 of 15,874). Among 344 contacts of patients with contact precautions, no transmissions were detected.
CONCLUSIONS: Reconsidering current MRSA contact tracing practices may lead to a more targeted approach with a lower number needed to screen.
Patients receive ADT SC or IM for up to 12 months in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy to the prostate bed over 2 - 6 weeks starting on week 8-10 of ADT hormone therapy. Additionally, patients undergo PET, CT or MRI and blood sample collection throughout the study.